home / lobbying / lobbying_activities

lobbying_activities: 756391

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
756391 d2a68dd2-37f7-434b-a489-87b55473e1ec Q1 THE UNITED STATES PHARMACOPEIAL CONVENTION 400358632 THE UNITED STATES PHARMACOPEIAL CONVENTION 2009 first_quarter PHA -GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA. Congressional Budget Office (CBO),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,President of the U.S.,SENATE   100000 0 0 2009-04-17T12:18:28-04:00
Powered by Datasette · Queries took 0.963ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API